Articles related to KIDNEY DISEASE

The FDA approved Furoscix ReadyFlow, a subcutaneous furosemide autoinjector for edema associated with heart failure or chronic kidney disease. Clinical data demonstrated pharmacokinetic exposure and diuretic effects comparable to intravenous furosemide.

A 31,000-patient observational study found that dihydropyridine calcium-channel blockers were associated with a 33% higher risk of major adverse kidney events in type 2 diabetes patients already on RASi and SGLT2i therapy.

Four major societies jointly published the first multidisciplinary guideline for cardiovascular-kidney-metabolic syndrome, introducing a standardized staging system and unified treatment framework across cardiology, nephrology, endocrinology, and primary care.

The 2026 KDIGO anemia in CKD guideline replaces two long-standing iron deficiency classifications, endorses proactive high-dose IV iron in maintenance hemodialysis, and provides first-ever positioning guidance on HIF-PHIs, 14 years after the previous version.

Infection-related complications remain the most significant cause for morbidity and technique failure in infants, children and adolescents who receive maintenance peritoneal dialysis (PD).

These medications can reduce blood flow through the kidneys, which can contribute to kidney damage or failure. Patients with heart failure, liver disease, or existing kidney problems are at a higher risk.